JP2019527711A - 局所ラパマイシン療法 - Google Patents

局所ラパマイシン療法 Download PDF

Info

Publication number
JP2019527711A
JP2019527711A JP2019506721A JP2019506721A JP2019527711A JP 2019527711 A JP2019527711 A JP 2019527711A JP 2019506721 A JP2019506721 A JP 2019506721A JP 2019506721 A JP2019506721 A JP 2019506721A JP 2019527711 A JP2019527711 A JP 2019527711A
Authority
JP
Japan
Prior art keywords
composition
rapamycin
treatment
skin
glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019506721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527711A5 (enExample
Inventor
メアリー ケイ コーニッグ，
メアリー ケイ コーニッグ，
ホープ ノースラップ，
ホープ ノースラップ，
アデレード エー． ヘバート，
アデレード エー． ヘバート，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2019527711A publication Critical patent/JP2019527711A/ja
Publication of JP2019527711A5 publication Critical patent/JP2019527711A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019506721A 2016-08-10 2017-08-10 局所ラパマイシン療法 Pending JP2019527711A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662372940P 2016-08-10 2016-08-10
US62/372,940 2016-08-10
PCT/US2017/046320 WO2018031789A1 (en) 2016-08-10 2017-08-10 Topical rapamycin therapy

Publications (2)

Publication Number Publication Date
JP2019527711A true JP2019527711A (ja) 2019-10-03
JP2019527711A5 JP2019527711A5 (enExample) 2020-08-20

Family

ID=59684091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019506721A Pending JP2019527711A (ja) 2016-08-10 2017-08-10 局所ラパマイシン療法

Country Status (11)

Country Link
US (1) US20190167649A1 (enExample)
EP (1) EP3496712A1 (enExample)
JP (1) JP2019527711A (enExample)
KR (1) KR20190039220A (enExample)
CN (1) CN109689053A (enExample)
AU (1) AU2017311491A1 (enExample)
BR (1) BR112019002689A2 (enExample)
CA (1) CA3032473A1 (enExample)
MX (1) MX2019001670A (enExample)
RU (1) RU2019106483A (enExample)
WO (1) WO2018031789A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021149827A1 (ja) * 2020-01-24 2021-07-29 ノーベルファーマ株式会社 ラパマイシン含有外用剤
JP2023550472A (ja) * 2020-11-24 2023-12-01 エーエフティー ファーマシューティカルズ リミテッド ラパマイシン組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
WO2019156999A1 (en) * 2018-02-06 2019-08-15 Georgetown University TOPICAL mTOR INHIBITORS FOR CUTANEOUS PROLIFERATIVE AND VASCULAR CONDITIONS
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
EP3829578A4 (en) * 2018-08-30 2022-08-17 Chemistryrx COMPOSITIONS CONTAINING SIROLIMUS
CN109431997B (zh) * 2018-12-20 2021-06-04 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法
JP2022521006A (ja) 2019-02-20 2022-04-04 エイアイ・セラピューティクス・インコーポレーテッド 局所ラパマイシン製剤ならびに顔面血管線維腫および他の皮膚疾患の治療におけるそれらの使用
WO2020175131A1 (ja) * 2019-02-27 2020-09-03 国立大学法人大阪大学 脈管異常治療用外用剤
AU2023203871B1 (en) * 2023-06-20 2024-07-25 Aft Pharmaceuticals Ltd A Rapamycin Method of Treatment and Composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120022095A1 (en) * 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
WO2012142145A1 (en) * 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
WO2015121836A1 (en) * 2014-02-14 2015-08-20 Druggability Technologies Ip Holdco Limited Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN105663027A (zh) * 2016-04-01 2016-06-15 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途
JP2018528236A (ja) * 2015-09-24 2018-09-27 ドレクセル ユニバーシティ 真皮障害を治療または予防するための新規組成物および方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
AU2003259803B2 (en) 2002-08-12 2007-08-02 The Regents Of The University Of Michigan Diagnosis and treatment of tuberous sclerosis
EP1853612A1 (en) 2005-03-02 2007-11-14 Wyeth Purification of rapamycin
AU2007211613C1 (en) 2006-02-02 2018-01-04 Novartis Ag Tuberous Sclerosis treatment
CA2899206C (en) * 2013-01-24 2019-07-09 Transderm, Inc. Compositions for transdermal delivery of mtor inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120022095A1 (en) * 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
WO2012142145A1 (en) * 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
WO2015121836A1 (en) * 2014-02-14 2015-08-20 Druggability Technologies Ip Holdco Limited Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
JP2018528236A (ja) * 2015-09-24 2018-09-27 ドレクセル ユニバーシティ 真皮障害を治療または予防するための新規組成物および方法
CN105663027A (zh) * 2016-04-01 2016-06-15 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEE J S; ET AL: "FAMILIAL MULTIPLE DISCOID FIBROMAS: UNIQUE HISTOLOGICAL FEATURES AND THERAPEUTIC 以下備考", BRITISH JOURNAL OF DERMATOLOGY, vol. VOL:169, NR:1, JPN5019007149, July 2013 (2013-07-01), GB, pages 177 - 180, ISSN: 0004902619 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021149827A1 (ja) * 2020-01-24 2021-07-29 ノーベルファーマ株式会社 ラパマイシン含有外用剤
JP2023550472A (ja) * 2020-11-24 2023-12-01 エーエフティー ファーマシューティカルズ リミテッド ラパマイシン組成物

Also Published As

Publication number Publication date
RU2019106483A (ru) 2020-09-11
WO2018031789A1 (en) 2018-02-15
US20190167649A1 (en) 2019-06-06
CA3032473A1 (en) 2018-02-15
MX2019001670A (es) 2019-07-04
CN109689053A (zh) 2019-04-26
BR112019002689A2 (pt) 2019-05-14
EP3496712A1 (en) 2019-06-19
RU2019106483A3 (enExample) 2020-12-04
AU2017311491A1 (en) 2019-02-07
KR20190039220A (ko) 2019-04-10

Similar Documents

Publication Publication Date Title
JP2019527711A (ja) 局所ラパマイシン療法
US8354424B2 (en) Method of treating actinic keratosis
US20130102572A1 (en) Methods of treating skin conditions exhibiting telangiectasia
JP7532511B2 (ja) Ｊａｋ阻害剤による尋常性白斑の局所治療
KR20140004186A (ko) 표면활성제 조성물
CN105792829A (zh) 使用伊维菌素治疗丘疹脓疱性红斑痤疮
JP2006522059A (ja) 皮膚疾患の処置にて使用するための免疫抑制剤を含んでなる医薬組成物
Stein et al. Betamethasone valerate foam for treatment of nonscalp psoriasis
ES2351045T3 (es) Utilización de una composición farmacéutica que comprende calcitriol y propionato de clobetazol para el tratamiento de la psoriasis.
Ramineni et al. Local delivery of imiquimod in hamsters using mucoadhesive films and their residence time in human patients
TWI863995B (zh) 皮膚型紅斑狼瘡之治療
JP6929860B2 (ja) 手湿疹の治療
US10772813B2 (en) Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis
US7357938B2 (en) Sulfacetamide formulations for treatment of rosacea
US7851431B2 (en) Treatment of actinic keratoses with calcium channel blockers
KR20070074624A (ko) 매크롤라이드 ｔ-세포 면역조절물질 및 광노화방지제를포함하는 제약 조성물
KR20230147668A (ko) 방사선으로 인한 피부 손상의 예방 및/또는 치료에 있어서의 하이드로겔 조성물 및 이의 용도
JP2023535463A (ja) 局所製剤
US20240189245A1 (en) Cyclosporine compositions and methods of use thereof
US20250255792A1 (en) Methods of Using a Small Molecule Chemical Compound to Reduce the Appearance of Rhytids and Wrinkles
US8501202B2 (en) Sulfacetamide formulations for treatment of skin dermatoses
Sigg et al. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium-and long-term efficacy and safety of topical rapamycin
AU2023343607A1 (en) Methods of using a small molecule chemical compound to reduce the appearance of rhytids and wrinkles
US20240342140A1 (en) Topical liquid compositions for treating hair loss
DeVillez Clinical Comparison of the Safety and Efficacy of Brevoxyl® Gel and Benzamycin® Gel

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221024